Scientific Conferences for The College on Problems of Drug Dependence (CPDD)

摘要 这是一份将R13 DA 013192资助金续期5年的申请，以继续支持以下旅行奖励： 学员和早期职业研究人员参加药物问题学院的年度会议， 依赖性（CPDD）。CPDD是致力于物质使用研究的最古老的科学协会。作为 唯一的年度国家或国际会议，汇集了研究人员研究的各个方面 和方法的物质使用的问题，CPDD的会议提供了一个特别 丰富该领域的受训人员和早期职业研究人员的经验。会议吸引了基本 来自美国各地和大约40个国家的临床研究人员， 从博士生到高级研究人员，以及政府和 行业它包括科学家、医生、护士、临床心理学家、管理人员、政策制定者， 记者和其他从事药物使用研究或对药物使用研究感兴趣的人。我们的会议是 来自广泛学科的研究人员（例如，药物化学，分子生物学， 药理学，遗传学，神经影像学，心理学，社会学，成瘾医学，公共卫生， 流行病学），以正式和非正式的方式分享他们最近的发现，建立网络并相互学习。 交流我们希望在我们未来的会议上有1000-1300名与会者， 竞争性更新在下一个资助期内，我们建议继续支持旅游奖励计划， 培训人员和早期职业研究人员参加CPDD年度会议。会议讨论的议题 满足新出现的问题和前沿研究领域的变化，而且，每年， 与NIDA的主要计划领域高度相关的会议（例如，流行病学、预防、健康 服务，药物开发，神经科学，行为，艾滋病毒/艾滋病和健康差距）是 包括.专题介绍涉及各种滥用药物，包括类阿片、兴奋剂、镇静剂， 大麻，致幻剂，尼古丁和酒精会议包括颁奖、讲座和论坛， 政策、动物和人类研究、行业/学术界/政府合作和媒体宣传， 以及针对受训人员、早期职业研究人员、代表性不足的少数民族 国际科学家。我们希望我们的年会能够加速物质使用方面的创新 通过我们内容的翻译性质和建立的合作进行研究 与会者之间的跨学科代表在会议上。我们也期待调查结果 由于我们的媒体外联活动， 开发虚拟产品，可显著改善药物使用的预防和治疗 疾病和告知政策，因为它涉及到物质的使用。

ABSTRACT This is a request for a 5-year renewal of grant R13DA013192 to continue to support travel awards for trainees and early career researchers to attend annual meetings of the College on Problems of Drug Dependence (CPDD). CPDD is the oldest scientific society dedicated to substance use research. As the only annual national or international meeting that brings together researchers studying all aspects and approaches to the problems of substance use, CPDD’s conference provides a particularly enriching experience for trainees and early career researchers in the field. The meeting attracts basic and clinical researchers from throughout the United States and about 40 countries, at all career stages from predoctoral students through senior investigators, as well as representatives from government and industry. It includes scientists, physicians, nurses, clinical psychologists, administrators, policy makers, journalists and others working on or interested in substance use research. Our meetings are a forum for researchers from a broad range of disciplines (e.g., medicinal chemistry, molecular biology, pharmacology, genetics, neuroimaging, psychology, sociology, addiction medicine, public health, epidemiology) to share their recent findings, network and learn from one another in formal and informal exchanges. We expect 1000-1300 attendees at each of our future meetings supported by this competing renewal. In the next funding period, we propose to continue to support travel awards for trainees and early career researchers to attend the CPDD annual meetings. Topics addressed at the meeting change with emerging concerns and cutting-edge research in the field, and, each year, sessions highly relevant to NIDA's major program areas (e.g., epidemiology, prevention, health services, medications development, neuroscience, behavior, HIV/AIDS and health disparities) are included. Presentations span the full range of drugs of abuse, including opioids, stimulants, sedatives, cannabis, hallucinogens, nicotine and alcohol. The conference includes awards lectures and forums on policy, animal and human research, industry/academia/government collaboration and media outreach, as well as activities directed towards trainees, early career researchers, underrepresented minorities and international scientists. We expect our annual meetings to accelerate innovation in substance use research through the translational nature of our content and through the collaborations that are built between attendees across the disciplines represented at the meeting. We also expect findings presented at the meeting to reach a broader audience due to our media outreach activities and newly developed virtual offerings, which can significantly improve prevention and treatment of substance use disorders and inform policy as it relates to substance use.